InflaRx N.V. (IFRX) At $22.50 Forms Top; Gtx (GTXI) Sellers Increased By 13.08% Their Shorts

February 6, 2018 - By Jerrie Dane

InflaRx N.V. (IFRX) formed multiple top with $24.53 target or 9.00% above today’s $22.50 share price. InflaRx N.V. (IFRX) has $526.75 million valuation. The stock decreased 1.10% or $0.25 during the last trading session, reaching $22.5. About 15,372 shares traded. InflaRx N.V. (NASDAQ:IFRX) has 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

Gtx Incorporated (NASDAQ:GTXI) had an increase of 13.08% in short interest. GTXI’s SI was 210,100 shares in February as released by FINRA. Its up 13.08% from 185,800 shares previously. With 38,200 avg volume, 6 days are for Gtx Incorporated (NASDAQ:GTXI)’s short sellers to cover GTXI’s short positions. The SI to Gtx Incorporated’s float is 2.82%. The stock decreased 0.84% or $0.12 during the last trading session, reaching $14.19. About 57,913 shares traded. GTx, Inc. (NASDAQ:GTXI) has declined 39.61% since February 6, 2017 and is downtrending. It has underperformed by 56.31% the S&P500.

Among 3 analysts covering GTx (NASDAQ:GTXI), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. GTx had 4 analyst reports since August 10, 2016 according to SRatingsIntel. Jefferies maintained GTx, Inc. (NASDAQ:GTXI) rating on Wednesday, August 10. Jefferies has “Hold” rating and $0.50 target. Jefferies maintained the shares of GTXI in report on Friday, December 9 with “Hold” rating.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. The company has market cap of $305.68 million. It focuses on the development of selective androgen receptor modulators for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). It currently has negative earnings. The companyÂ’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.